GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » Median PS Value

Atara Biotherapeutics (Atara Biotherapeutics) Median PS Value : $0.00 (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Atara Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.08. Atara Biotherapeutics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-04-28), Atara Biotherapeutics's share price is $0.69. Atara Biotherapeutics's Median PS Value is $0.00. Therefore, Atara Biotherapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Atara Biotherapeutics's Median PS Value or its related term are showing as below:

ATRA's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.65
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Atara Biotherapeutics Median PS Value Historical Data

The historical data trend for Atara Biotherapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Median PS Value Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Atara Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Atara Biotherapeutics's Median PS Value

For the Biotechnology subindustry, Atara Biotherapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Price-to-Median-PS-Value falls into.



Atara Biotherapeutics Median PS Value Calculation

Atara Biotherapeutics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.08*0
=0.00

10-Year Median PS Ratio is 0.
Atara Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atara Biotherapeutics  (NAS:ATRA) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Atara Biotherapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.69/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atara Biotherapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (Atara Biotherapeutics) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Executives
Jill Henrich officer: EVP, Global Head RA & Quality 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Pascal Touchon director, officer: President and CEO C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD SUITE 900, SOUTH SAN FRANCISCO CA 94080
Amar Murugan officer: SVP, GC & Secretary C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD,SUITE 900, SOUTH SAN FRANCISCO CA 94080
Eric J Hyllengren officer: SVP, CFO 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Anhco Nguyen officer: EVP, Chief Sci. & Tech Officer 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Manher Joshi officer: EVP, Chief Medical Officer 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Eric Dobmeier director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Charlene A. Banard officer: EVP, Chief Technical Officer C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
Jakob Dupont officer: EVP, Head of R&D C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Utpal Koppikar officer: Chief Financial Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Ameet Mallik director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Kristin Yarema officer: Chief Commercial Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Joe Newell officer: Chief Tech. Operations Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO CA 94080